Labmein
Problem and implemented solution
According to the World Health Organisation's data, there are approximately 18 million deaths caused by cardiovascular diseases around the world (2021), where almost 11 million patients dead because of atherosclerosis of coronary arteries, which is a reason for the ischemic heart disease and a heart attack. We present nanoparticles with a remote magnetic control which can transport special medicine for decreasing lipid nucleus of a plaque as a new method for fast, mini-invasive and effective treatment of cardiovascular patients with atherosclerosis
Nomination
Biotechnology And National Health
Topic
Technologies for human health
Estimated duration of implementation
The project has been started since 2022
Implementation geography
Moscow, Russia
Description of competitive advantages
Advantages:
fast way to prevent acute coronary syndrom;
biodegradable materials;
remote magnetic control;
mini-invasive intervention to a patient's body;
much less amount of postoperative complications;
financial affordability.
List of awards and prizes, media articles about the organization/individual or the Practice
Agreement with the Natioanal Asset Management Fund, Armenia Ministry of High Tech Industry, winners in Sber accelerator (2022), winners in the Academy of innovators in the Lomonosov Moscow innovative claster (2023), participants and winners of the BRICS Business Incubator (2023), interviews for Russian media such as Moscow 24, Russia 1 (Omsk local news), Moscow Centre of innovative technologies in healthcare, BRICS news, Sber,
List of scientific works and IP connected with the Practice
Primitive and incomplete preclinical studies have been conducted where the team have proven biocompatibility, a lack of the immune system's reaction,
